8-K: Monogram Orthopaedics Advances mBs Surgical System with Favorable FDA Feedback, Eyes Second Half 2024 Submission

Monogram Orthopaedics is progressing towards a 510(k) submission for its mBs surgical system in the second half of 2024, following constructive feedback from the FDA.

Summary

• Monogram Orthopaedics received positive feedback from the FDA regarding their mBs surgical system, specifically related to their pre-submission request.
• The FDA's feedback supports a least burdensome approach to acquiring clinical data, potentially saving the company significant cost and time.
• The company plans to conduct an outside-the-U.S. (OUS) clinical trial involving approximately 100 knee surgeries at three sites with three months of follow-up.
• The estimated cost for the OUS clinical trial is approximately $1.5 million.
• Monogram anticipates completing verification and validation testing in the first half of 2024 and submitting the 510(k) application in the second half of 2024.
• The company has modified the mBs TKA System to reduce the likelihood of an FDA clinical data request.
• Monogram has engaged MCRA, a Contract Research Organization, to support its regulatory strategy.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the favorable FDA feedback, the potential for cost savings with the OUS clinical trial, and the progress towards a 510(k) submission. The company appears to be on track with its regulatory strategy.

Positives

• The FDA's feedback was comprehensive and is expected to be advantageous for a successful 510(k) submission.
• The FDA supports a least burdensome approach to clinical data, potentially reducing costs and time for Monogram.
• The proposed testing plan appears acceptable to address technical differences with the predicate device.
• The company's verification and validation plan appears to satisfy all the FDA's stated concerns.
• Monogram's engagements with the FDA have been highly constructive.
• The company has completed various mandated packaging, biocompatibility, sterilization, and cleaning validations.

Negatives

• The company has not yet made 510(k) premarket notification submissions or obtained 510(k) clearances for its robotic products.
• FDA approval is required to market these products, and the company has not obtained FDA approval for any of its robotic products.
• The company cannot estimate the timing or assure the ability to obtain such clearances.

Risks

• The company's lack of profitability and need for additional capital to grow its business are ongoing risks.
• The company is dependent on partners to further the development of its product candidates.
• There are uncertainties inherent in the development, attainment of regulatory authorizations, and launch of any new product.
• The outcome of pending or future litigation could impact the company.
• Actual events or results may differ materially from forward-looking statements.

Future Outlook

Monogram anticipates completing verification and validation testing in the first half of 2024, submitting a 510(k) application in the second half of 2024, and commencing OUS live-patient surgery trials in the second half of 2024. The company also plans to establish an ongoing OUS clinical strategy to support its innovation strategy.

Management Comments

• Ben Sexson, Chief Executive Officer of Monogram, stated that the team has been actively executing extensive testing while incorporating feedback from the FDA.
• Ben Sexson stated that they continue to expect verification and validation to be largely complete in H1 2024, with a planned FDA 510(k) submission in H2 2024.
• Dave McGurl, Vice President, Regulatory Affairs at MCRA, commented that Monogram's engagements with the FDA have been highly constructive.
• Dave McGurl stated that the company should be set up for success with the 510(k) submission to the FDA for clearance.

Industry Context

This announcement is significant for the orthopedic robotics industry as it demonstrates progress in regulatory pathways for new surgical technologies. The use of OUS clinical data could set a precedent for other companies seeking FDA clearance, potentially accelerating the adoption of innovative medical devices.

Comparison to Industry Standards

• The use of OUS clinical data is becoming more common in the medical device industry, particularly for companies seeking to reduce the time and cost of regulatory approvals. Companies like Medtronic and Stryker have also utilized OUS data in their regulatory submissions.
• The estimated cost of $1.5 million for the OUS clinical trial is relatively low compared to the costs of running similar trials in the US, which can range from $5 million to $20 million depending on the complexity and size of the trial.
• The timeline for 510(k) submission in the second half of 2024 is consistent with industry standards for medical device companies that have completed their verification and validation testing.

Stakeholder Impact

• Shareholders may view the positive FDA feedback and progress towards regulatory approval favorably.
• The potential for cost savings with the OUS clinical trial could improve the company's financial outlook.
• The successful launch of the mBs surgical system could benefit patients by providing a better-fitting knee replacement with minimally invasive surgery.

Next Steps

• Complete verification and validation testing in H1 2024.
• Submit a 510(k) application to the FDA in H2 2024.
• Commence OUS live-patient surgery trials in H2 2024.
• Establish an ongoing OUS clinical strategy to support its innovation strategy.

Key Dates

Keywords

Orthopaedics, Robotics, FDA, 510(k), Clinical Trial, mBs Surgical System, Regulatory Approval, Knee Replacement, Medical Devices, AI